In this study, we found that treatment of melanoma cells with BCI, a DUSP1/DUSP6 inhibitor at a concentration close to IC50 for selective inhibition of DUSP1, caused upregulation of nestin and immature MAP2 in MAPKi-sensitive cells. Here, MAP2 is linked to melanoma.